EP1284146A1 - Hydrophobe iodverbindung enthaltende liposome - Google Patents

Hydrophobe iodverbindung enthaltende liposome Download PDF

Info

Publication number
EP1284146A1
EP1284146A1 EP01925960A EP01925960A EP1284146A1 EP 1284146 A1 EP1284146 A1 EP 1284146A1 EP 01925960 A EP01925960 A EP 01925960A EP 01925960 A EP01925960 A EP 01925960A EP 1284146 A1 EP1284146 A1 EP 1284146A1
Authority
EP
European Patent Office
Prior art keywords
smooth muscle
liposome
muscle cells
vascular smooth
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01925960A
Other languages
English (en)
French (fr)
Other versions
EP1284146A4 (de
EP1284146B1 (de
Inventor
Kazuhiro c/o FUJI PHOTO FILM CO. LTD AIKAWA
Hiroshi c/o FUJI PHOTO FILM CO. LTD KITAGUCHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fuji Photo Film Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Photo Film Co Ltd filed Critical Fuji Photo Film Co Ltd
Publication of EP1284146A1 publication Critical patent/EP1284146A1/de
Publication of EP1284146A4 publication Critical patent/EP1284146A4/de
Application granted granted Critical
Publication of EP1284146B1 publication Critical patent/EP1284146B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles

Definitions

  • the present invention relates to a liposome. More specifically, the invention relates to a liposome that can be utilized for a method for selectively accumulating a hydrophobic iodine compound in a pathological lesion and imaging said lesion in contrast to non-pathological site.
  • Methods for diagnosing arteriosclerosis are basically classified into non-invasive methods and invasive methods in which a catheter or the like is inserted into an artery.
  • typical non-invasive methods include X-ray angiography and ultrasonography.
  • CT, MRI and the like may sometimes be used as another class of non-invasive methods.
  • these methods have been mainly developed for detection of tumors, and accordingly, they have a problem of a low resolution of arteriosclerotic lesions.
  • the methods require expensive and large-scale apparatuses, which limits employable hospitals and general applicability.
  • methods utilizing radioisotopes have also been investigated. However, these methods still remain at an experimental level.
  • a method most widely used for identification of a lesion of arterial vasoconstriction is X-ray angiography.
  • This method comprises the step of administration of a water-soluble iodine contrast medium to visualize vascular flows, and detecting a lesion at which the flows are obstructed.
  • these methods can only detect a lesion where constriction progresses 50% or more and fail to detect a lesion before the onset of attack of an ischemic disease.
  • J. Pharm. Sci. 72 (8), 898 (1983) discloses examples of X-ray hepatography and splenography by injection of an oil-particle dispersion of cholesteryl iopanoate.
  • U.S. Patent No. 4,567,034 describes a method of selective hepatography or splenography utilizing liposomes encapsulating an ester of diatrizoic acid.
  • International Patent Publications WO96/28414 and WO96/00089 disclose contrast media for imaging vascular pools or lymphatic systems. However, the methods using these formulations are not satisfactory in efficiency and selectivity for a purpose of selective contrast of vascular diseases, and no example thereof is reported in which vascular diseases are imaged by utilizing X-ray irradiation.
  • An object of the present invention is to provide means for selectively accumulating an iodine compound in a lesion of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells such as arteriosclerosis and restenosis after PTCA.
  • Another object of the present invention is to provide a means for imaging of a biological environment of a vascular disease or the like by X-ray radiography using the aforementioned means.
  • the inventors of the present invention conducted various studies to achieve the foregoing objects, and as a result, they found that liposomes containing a hydrophobic iodine compound as one of membrane components accumulated in vascular smooth muscle cells and foam macrophages, which are main components of arteriosclerotic lesion.
  • a further object of the present invention is to provide a cell culture system reproducing a state of lesion of arteriosclerosis, restenosis or the like and a method for producing such a cell culture system.
  • Another object of the present invention is to provide a method for evaluating a drug for arterial diseases by using the aforementioned means.
  • the inventors of the present invention conducted various studies to achieve the foregoing objects, and as a result, they found that a cell culture system reproducing a state of lesion of arteriosclerosis, restenosis or the like was successfully provided by simultaneously culturing in a single cell culture vessel two or more kinds of cell species that form a lesion of a mammalian disease. The present invention was achieved on the basis of these findings.
  • the present invention thus provides a liposome containing a hydrophobic iodine compound as a membrane component.
  • the hydrophobic iodine compound is a 1,3,5-triiodobenzene derivative having at least one substituent containing 18 or more carbon atoms;
  • the aforementioned liposome which contains a lipid selected from the group consisting of phosphatidylcholines and phosphatidylserines as a membrane component;
  • the aforementioned liposome which contains a phosphoric acid dialkyl ester which is a diester of an alkyl containing 6 or more carbon atoms as a membrane component;
  • the aforementioned liposome wherein the substituent containing 18 or more carbon atoms is a residue of a cholesterol derivative.
  • the present invention provides an X-ray contrast medium, which comprises the aforementioned liposome.
  • the aforementioned X-ray contrast medium which is used for radiography of a vascular disease, preferably radiography of vascular smooth muscle cells which are abnormally proliferated under an influence of foam macrophages, for example, for radiography of an arteriosclerotic lesion or restenosis after PTCA.
  • the present invention also provides a method for contrasting a vascular disease, which comprises a step of X-ray radiography using the aforementioned liposome, and use of the aforementioned liposome for the manufacture of the aforementioned X-ray contrast medium.
  • the present invention provides a method for preparing a cell culture system, which comprises a step of simultaneously culturing, in a single cell culture vessel, two or more kinds of cell species which are involved in formation of a lesion of a mammalian disease.
  • the cell species comprise primary culture cells isolated from a living body or established subculture cells; the aforementioned method, wherein the cell species comprise mammalian primary culture cells; and the aforementioned method, wherein the mammalian disease is a human disease.
  • the aforementioned method wherein at least one of the cell species consists of cells involved in formation of arteriosclerotic lesion; the aforementioned method, wherein the cell species are selected from the group consisting of macrophages, vascular smooth muscle cells, and vascular endothelial cells; the aforementioned method, which comprises a step of culturing two kinds of cell species, in a single culture vessel, under being partitioned off by means of a cell filter; and the aforementioned method, wherein the two kinds of cell species consist of macrophages and vascular smooth muscle cells.
  • a method for producing a cell culture system that reproduces a state of an arteriosclerotic lesion which comprises simultaneously culturing in a single culture vessel two kinds of mammalian primary culture cells involved in formation of arteriosclerotic lesion under being partitioned off by mean of a cell filter.
  • the present invention further provides a cell culture system, which is obtainable by the aforementioned method for producing a cell culture system.
  • the present invention also provides a method for screening a drug by using a cell culture system that is obtainable by the aforementioned method for producing a cell culture system.
  • the present invention provides a method for determining effectiveness of a drug on a vascular disease, which comprises determining action of the drug on vascular smooth muscle cells proliferated by culturing foam macrophages and the vascular smooth muscle cells under being partitioned off by means of a cell filter; and a method for evaluating permeation ability of a drug into a lesion of vascular disease, which comprises measuring action of the drug on vascular smooth muscle cells proliferated by culturing foam macrophages and the vascular smooth muscle cells under being partitioned off by means of a cell filter.
  • Fig. 1 shows results of induction of mouse vascular smooth muscle cell proliferation in the presence of foam mouse macrophages.
  • Fig. 2 shows a proliferation curve of mouse vascular smooth muscle cells obtained without addition of foam mouse macrophages.
  • Fig. 3 shows results of induction of rat vascular smooth muscle cell proliferation in the presence of foam rat macrophages.
  • Fig. 4 shows results of induction of rabbit vascular smooth muscle cell proliferation in the presence of foam rabbit macrophages.
  • Fig. 5 shows uptake of liposomes by mouse vascular smooth muscle cells.
  • (1) shows results obtained by adding a liposome preparation after 3 days to the culture system of Fig. 2 not added with foam macrophages, and then continuing the culture for 1 day
  • (2) shows results obtained by adding a liposome preparation after 5 days to the culture system of Fig. 1 which was added with foam macrophages, and then continuing culture for 1 day
  • (3) shows results obtained by adding a liposome preparation after 7 days to the culture system of Fig. 1 which was added with foam macrophages, and then continuing culture for 1 day.
  • Fig. 6 shows the results obtained by using an oil-particle dispersion instead of the liposomes of the present invention.
  • Fig. 7 shows uptake of liposomes by rat vascular smooth muscle cells cultured under the culture conditions mentioned in Fig. 3.
  • (1), (2) and (3) have the same meanings as those mentioned in Fig. 5.
  • Fig. 8 shows uptake of liposomes by rabbit vascular smooth muscle cells cultured under the culture conditions mentioned in Fig. 4.
  • (1), (2) and (3) have the same meanings as those mentioned in Fig. 5.
  • Fig. 9 depicts photographs showing the results of X-ray radiography of arteriosclerotic lesions by using the liposomes of the present invention.
  • "before administration” indicates the result obtained before administration of liposomes
  • “after administration” indicates the result obtained immediately after administration of liposomes.
  • Fig. 10 depicts photographs showing the results of X-ray radiography of arteriosclerotic lesions using the liposomes of the present invention.
  • “15 minutes after administration” indicates the result obtained 15 minutes after administration of liposomes
  • “30 minutes after administration” indicates the result obtained 30 minutes after administration of liposomes.
  • a type of the hydrophobic iodine compound is not particularly limited.
  • an iodobenzene derivative is preferred. More preferred is a 1,3,5-triiodobenzene derivative having at least one substituent having 18 or more carbon atoms.
  • the substituent having 18 or more carbon atoms is preferably a hydrophobic group for stable localization of the 1,3,5-triiodobenzene residue, as being an iodine contrasting moiety, in a bilayer of the liposome.
  • the hydrophobic substituent more preferably has a structure similar to that of lipid components constituting biological membranes.
  • cholesterol derivatives those described in the aforementioned publications are preferred, and cholesterol is particularly preferred.
  • a hydrophobic iodine compound such as 1,3,5-triiodobenzene
  • For binding of the hydroxyl group of cholesterol and the hydrophobic iodine compound such as 1,3,5-triiodobenzene for example, means such as an ester bond, ether bond, urethane bond, and carbonic acid ester bond can be used. An ester bond is preferred.
  • Cholesterol and the hydrophobic iodine compound such as 1,3,5-triiodobenzene may be directly bound via any of the aforementioned bonds, or bound via an appropriate bridging group.
  • suitable bridging group include a linear or branched alkylene group having 5 or less carbon atoms.
  • the hydrophobic iodine compound may have one or more substituents other than the aforementioned substituent having 18 or more carbon atoms.
  • the type, substituting position and numbers of the substituents are not particularly limited.
  • a substituted or unsubstituted amino group, a substituted or unsubstituted acylamino group, a hydroxyl group, a carboxyl group or the like substitutes on the benzene ring of the hydrophobic iodine compound.
  • Preferred substituents are a substituted or unsubstituted amino group and a substituted or unsubstituted acylamino group.
  • Examples of the amino group having a substituent include a monoalkylamino group, a dialkylamino group and the like, and examples of the acylamino group having a substituent include trifluoroacetylamino group, p-chlorobenzoylamino group and the like.
  • hydrophobic iodine compound examples include those containing these compounds.
  • the hydrophobic iodine compound is contained as a component of a membrane of the liposome, and a content of the compound in the liposome is about from 10 to 90 mass %, preferably from 10 to 80 mass %, more preferably from 20 to 80 mass %, based on the total mass of the membrane components of the liposome.
  • One kind of the hydrophobic iodine compound may be used as a membrane component, or two or more kinds of the hydrophobic iodine compounds may be used in combination.
  • any of lipid compounds ordinarily used for preparation of liposomes can be used.
  • such compounds are described in Biochim. Biophys. Acta, 150 (4), 44 (1982); Adv. in Lipid. Res., 16 (1) 1 (1978); "RESEARCH IN LIPOSOMES", P. Machy, L. Leserman, John Libbey EUROTEXT Co.; “Liposome” (Ed., Nojima, Sunamoto and Inoue, Nankodo) and the like.
  • phospholipids are preferred, and phosphatidylcholines (PC) are particularly preferred.
  • Preferred examples of phosphatidylcholines include, but not limited thereto, egg PC, dimyristoyl-PC (DMPC), dipalmitoyl-PC (DPPC), distearoyl-PC (DSPC), dioleyl-PC (DOPC) and the like.
  • DMPC dimyristoyl-PC
  • DPPC dipalmitoyl-PC
  • DSPC distearoyl-PC
  • DOPC dioleyl-PC
  • a phosphatidylcholines and a phosphatidylserine can be used in combination.
  • the phosphatidylserines include those having lipid moieties similar to those of the phospholipids mentioned as preferred examples of the phosphatidylcholines.
  • molar ratio of PC and PS (PC:PS) used is preferably in the range of 90:10 to 10:90, further preferably 30:70 to 70:30.
  • Another preferred embodiment of the liposome of the present invention includes the liposome containing a phosphatidylcholine and a phosphatidylserine and further containing a phosphoric acid dialkyl ester as membrane components.
  • the two alkyl groups constituting the dialkyl ester of phosphoric acid are preferably the same groups. Each group may contain 6 or more carbon atoms, preferably 10 or more carbon atoms, more preferably 12 or more carbon atoms.
  • Preferred examples of the phosphoric acid dialkyl ester include, but not limited thereto, dilauryl phosphate, dimyristyl phosphate, dicetyl phosphate and the like.
  • preferred amount of the phosphoric acid dialkyl ester is from 1 to 50 mass %, preferably from 1 to 30 mass %, further preferably from 1 to 20 mass %, based on the total mass of phosphatidylcholine and phosphatidylserine.
  • preferred weight ratio of PC, PS, phosphoric acid dialkyl ester and hydrophobic iodine compound may be chosen from 5 to 40 mass % : from 5 to 40 mass % : from 1 to 10 mass % : from 15 to 80 mass %.
  • the components of the liposome of the present invention are not limited to the aforementioned four kinds of compounds, and other components may be added.
  • examples of such components include cholesterol, cholesterol esters, sphingomyelin, monosial ganglioside GM1 derivatives described in FEBS Lett., 223, 42 (1987); Proc. Natl. Acad. Sci., USA, 85, 6949 (1988) etc., glucuronic acid derivatives described in Chem. Lett., 2145 (1989); Biochim. Biophys. Acta, 1148, 77 (1992) etc., polyethylene glycol derivatives described in Biochim. Biophys. Acta, 1029, 91 (1990); FEBS Lett., 268, 235 (1990) and the like.
  • the components are not limited to these examples.
  • the liposome of the present invention can be prepared by any methods known in the field of the art. Examples of the preparation method are described in the references as general review of liposomes, which are mentioned above, as well as in Ann. Rev. Biophys. Bioeng., 9, 467 (1980), "Liopsomes” (Ed. by M.J. Ostro, MARCELL DEKKER, INC.) and the like. Specific examples include, but not limited thereto, the ultrasonication method, ethanol injection method, French press method, ether injection method, cholic acid method, calcium fusion method, freeze and thawing method, reverse phase evaporation method and the like. Size of the liposome of the present invention may be any of those obtainable by the aforementioned methods.
  • a size in average may be 400 nm or less, preferably 200 nm or less.
  • Structure of the liposome is not particularly limited, and may be unilamellar or multilamellar structure. It is also possible to formulate one or more kinds of appropriate drugs or other contrast media in the liposome.
  • the liposomes of the present invention When used as a contrast medium, they can be preferably administered parenterally, more preferably administered intravenously.
  • preparations in the form of an injection or a drip infusion can be provided as powdery compositions in a lyophilized form, and they can be used by being dissolved or resuspended just before use in water or an appropriate solvent (e.g., physiological saline, glucose infusion, buffering solution and the like).
  • an appropriate solvent e.g., physiological saline, glucose infusion, buffering solution and the like.
  • vascular smooth muscle cells constituting tunica media of blood vessel abnormally proliferate and migrate into endosporium at the same time to narrow blood flow passages.
  • triggers that initiate the abnormal proliferation of normal vascular smooth muscle cells have not yet been clearly elucidated, it is known that migration of macrophages into endosporium and foaming are important factors. It is reported that vascular smooth muscle cells then cause phenotype conversion (from constricted to composite type).
  • the hydrophobic iodine compound can be selectively taken up into the vascular smooth muscle cells abnormally proliferated under influences of foam macrophages.
  • the contrast medium of the present invention can be suitably used particularly for X-ray radiography of vascular diseases.
  • radiography of arteriosclerotic lesion or restenosis after PTCA can be performed.
  • Method for imaging is not particularly limited. Imaging can be performed by, for example, a method utilizing X-ray irradiation, radionuclide imaging utilizing an radioactive iodine-labeled compound and the like. However, the method is not limited to these.
  • the method for producing a cell culture system is characterized to comprise a step of culturing, in a single cell culture vessel, two or more kinds of cell species which are involved in formation of lesion of a mammalian disease.
  • cell species primary culture cells and established subculture cells are preferred, and mammalian primary culture cells are particularly preferred.
  • Preferred mammals include, but not limited thereto, human, dog, cat, pig, miniature pig, rabbit, hamster, rat, mouse and the like.
  • Type of the culture vessel is not particularly limited, and for example, culture flask, culture test tube, dish, microplate and the like can be suitably used.
  • the two or more kinds of different cell species cultured in a single culture vessel may be derived from homologous animals or heterogenous animals. They may preferably be derived from homologous animals.
  • the term "involved in formation of a lesion” should be construed in its broadest sense, including a condition where plural kinds of cells form a lesion under mutual control of proliferation and the like, and the term should not be construed in any limitative sense.
  • the different cell species it is preferred to chose cell species different from cytobiological y or cytotaxonomical viewpoint. More preferably, two kinds of cell species may be chosen that coexist in a certain lesion and form the lesion under mutual control of proliferation. For example, macrophages and vascular smooth muscle cells, which coexist in an arteriosclerotic lesion, are preferably chosen as the two kinds of cell species.
  • the two kinds of cell species can be cultured in a single well under being partitioned off by means of a cell filter.
  • the two kinds of cell species used are preferably cells that form an arteriosclerotic legion.
  • Preferred cell species include macrophages, vascular smooth muscle cells, vascular endothelium cells, T cells, mast cells and the like.
  • preferred cell species include macrophages, vascular smooth muscle cells and vascular endothelium cells, and particularly preferred cell species include a combination of macrophages and vascular smooth muscle cells.
  • the macrophages are preferably made into foam cells beforehand.
  • a method for evaluation of permeation ability of a drug into a lesion of a vascular disease which comprises a step of measuring action of the drug on vascular smooth muscle cells which are proliferated by culturing foam macrophages and the vascular smooth muscle cells under being partitioned off by means of a cell filter.
  • action of drug used in the specification should be construed in its broadest sense including therapeutic effect, diagnostic effect and the like.
  • Types of the cell filter are not particularly limited so long as they have such a pore size that does not allow foam macrophages and vascular smooth muscle cells to pass through pores.
  • a filter having a pore size of 0.4 ⁇ m or less can be used as a pore size that does not allow the cells to pass through pores.
  • a cell filter having an appropriate pore size can be easily chosen.
  • foam macrophages and vascular smooth muscle cells are cultured under being partitioned off by means of a cell filter, a proliferation activating substance derived from the foam macrophages acts on the vascular smooth muscle cells to induce their proliferation, and thus abnormal proliferation of vascular smooth muscle cells in a vascular disease such as arteriosclerosis and restenosis after PTCA can be reproduced in vitro.
  • Investigation of uptake of drugs into the proliferated vascular smooth muscle cells enables screening of a drug having a high effectiveness on vascular diseases such as arteriosclerosis and restenosis after PTCA.
  • Example 1 Preparation of culture system of vascular smooth muscle cells of which proliferation is activated by foam macrophages (1)
  • vascular smooth muscle cells were isolated from mouse aorta endothelium ("Tissue Culture Method", 10th Edition, ed. by the Japanese Tissue Culture Association, published by Kodansha, 1998). The isolated vascular smooth muscle cells were suspended in 10% FBS Eagle's MEM (GIBCO, No. 11095-080) and inoculated in wells of a 12-well microplate (FALCON, No. 3503). The number of the cells in each well was adjusted to 10,000 cells. The cells were cultured for 3 days under conditions of 37°C and 5% CO 2 .
  • foam mouse peritoneal macrophages were prepared according to the method described in Biochimica Biophysica Acta, 1213, 127 (1994). 200,000 cells of the foam macrophages were separated and inoculated on an insert cell (FALCON, No. 3180) placed on each well of the microplate where the vascular smooth muscle cells were cultured on the bottom surface. The cells were cultured for 5 days under conditions of 37°C and 5% CO 2 .
  • the cell numbers of the vascular smooth muscle cells in the above experiment are shown in Fig. 1. Although the vascular smooth muscle cells gently proliferated at an early stage after the start of the culture, they actively proliferated after the addition of the foam macrophages after 3 days and a subsequent induction period of about 1 day. A proliferation curve of vascular smooth muscle cells not added with the macrophages is shown in Fig. 2. Comparison of the results shown in Figs. 1 and 2 clearly indicates activating effect of the foam macrophages on the proliferation.
  • Example 2 Verification of expression of scavenger receptors on vascular smooth muscle cells
  • vascular smooth muscle cells in an arteriosclerotic lesion express scavenger receptors on their surfaces to take up oxidized LDL (Biochem. Phamacol., 15:57 (4), 383-6 (1999); Exp. Mol. Pathol., 64 (3), 127-45, 1997).
  • the vascular smooth muscle cells of the culture system of Fig. 1 were immunostained by using mouse scavenger receptor antibodies. As a result, although the expression was not observed on the vascular smooth muscle cells on the 3rd day from the inoculation, clear staining was observed on the 6th day from the inoculation. When the foam macrophages on the cell filter were also similarly immunostained, clear staining was also observed.
  • Example 3 Uptake of oxidized LDL by vascular smooth muscle cells
  • 125 I-labeled oxidized LDL was added to the medium for the vascular smooth muscle cells on the 3rd day and 6th day from the inoculation. 125 I taken up into the cells was counted 24 hours after each addition. The results are shown in Table 1. Clear difference in uptake amount was observed between the results on the 3rd day and 6th day. The above results indicate that the vascular smooth muscle cells cultured in the cell culture system of the present invention had properties similar to those of smooth muscle cells in a lesion of arteriosclerosis, restenosis or the like. Day Uptake of 125 I-oxLDL 3rd Day from inoculation 0.52 ⁇ 0.11 6th Day from inoculation 2.2 ⁇ 0.4 ⁇ 10,000 cpm
  • Example 4 Preparation of culture system of vascular smooth muscle cells of which proliferation is activated by foam macrophages (2)
  • vascular smooth muscle cells cultured in the culture system in Fig. 1 had properties of healthy blood vessel until the 3rd day from the inoculation and properties of smooth muscle cells in an arteriosclerotic lesion on and after the 7th day from the inoculation. Accordingly, a screening of a drug selective to the lesion can be performed by comparing actions of the drug on each of the above cells.
  • the system can be utilized for searching of a drug delivery system selective to a lesion, searching of a drug that is selectively toxic for cells in a lesion, searching of a drug that selectively terminates cell cycle of cells in a lesion and the like. Specific examples will be given below. However, the present invention is not limited to these examples.
  • Egg PC (Funakoshi, No. 1201-41-0214), egg PS (Funakoshi, No.1201-42-0226), dicetyl phosphate (DCP, Funakoshi, No.1354-14-8165) and Hydrophobic iodine compound (3) synthesized by the method described in J. Med. Chem., 25 (12), 1500 (1982), in the ratios described blow, were dissolved in methylene chloride contained in an eggplant-shaped flask to form a uniform solution, and then the solvent was evaporated under reduced pressure to form a thin membrane on the bottom of the flask. The thin membrane was dried in vacuo, then added with 1.5 ml of 0.9% physiological saline (Hikari Pharmaceutical, No.
  • Example 5 The three types of liposomes prepared in Example 5 were added to the smooth muscle cell culture system of Fig. 1 or 2 in Example 1 according to the following conditions (1), (2) and (3), and then the culture was continued.
  • An oil particle suspension of Compound (3) was prepared according to the method described in Pharm. Res., 16, (3) 420 (1999). The suspension was added to the cell culture system under the same conditions as those used in Example 6 (conditions (1), (2) and (3)) with the same amount of Compound (3), and amounts of Compound (3) taken up into the vascular smooth muscle cells were measured by HPLC. The results are shown in Fig. 6. From comparison of the results shown in Figs. 5 and 6, it is clearly understood that, by using the liposomes of the present invention, the iodine-containing contrast medium can be more efficiently and more selectively accumulated than the known oil particle suspension in the vascular smooth muscle cells abnormally proliferating under influence of foam macrophages.
  • Example 5 The three types of liposomes prepared in Example 5 were added to the smooth muscle cell culture systems of rat (Fig. 3) and rabbit (Fig. 4) prepared in Example 4 according to the aforementioned conditions (1), (2) and (3), and the culture was continued. Amounts of Compound (3) taken up into the cells were measured by HPLC. The results are shown Figs. 7 and 8. Each system gave results similar to those shown in Fig. 5 for mouse cells.
  • Arteriosclerotic lesions were formed in a rat aorta according to the method described in Invest. Radiol. 18, 275 (1983). Liposome preparation 3 prepared in Example 2 was carefully administered to the rat in which arteriosclerotic lesions were formed in an amount of 200 mg/kg as an MTD amount converted to be an amount of Compound (3). Thirty minutes after the administration, clear X-ray radiographic photographs of the arteriosclerotic lesions was obtained. The results are shown in Figs. 9 and 10.
  • the liposomes of the present invention can achieve accumulation of iodine compounds in vascular smooth muscle cells abnormally proliferating under influence of foam macrophages, and are useful as an X-ray contrast medium for selective radiography of a lesion of a vascular disease caused by abnormal proliferation of vascular smooth muscle cells.
  • the culture systems provided by the method for preparing a culture system of the present invention can be utilized, as cell culture systems in which a state of lesion of arteriosclerosis, restenosis or the like is reproduced, for in vitro screening of drugs and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
EP01925960A 2000-04-28 2001-04-26 Hydrophobe iodverbindung enthaltende liposome Expired - Lifetime EP1284146B1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000130069 2000-04-28
JP2000130069 2000-04-28
JP2001018573 2001-01-26
JP2001018573 2001-01-26
PCT/JP2001/003629 WO2001082977A1 (fr) 2000-04-28 2001-04-26 Liposomes contenant un compose iodo hydrophobe

Publications (3)

Publication Number Publication Date
EP1284146A1 true EP1284146A1 (de) 2003-02-19
EP1284146A4 EP1284146A4 (de) 2004-12-22
EP1284146B1 EP1284146B1 (de) 2007-06-06

Family

ID=26591162

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01925960A Expired - Lifetime EP1284146B1 (de) 2000-04-28 2001-04-26 Hydrophobe iodverbindung enthaltende liposome

Country Status (9)

Country Link
US (1) US7101532B2 (de)
EP (1) EP1284146B1 (de)
KR (1) KR100824068B1 (de)
AT (1) ATE363920T1 (de)
AU (2) AU5260301A (de)
CA (1) CA2407654C (de)
DE (1) DE60128800T2 (de)
NZ (1) NZ522457A (de)
WO (1) WO2001082977A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375173T1 (de) 2001-08-20 2007-10-15 Fujifilm Corp Hydrophobe iodverbindung enthaltendes liposom und dieses enthaltendes röntgenkontrastmittel
JP4198592B2 (ja) * 2001-08-23 2008-12-17 富士フイルム株式会社 二個のヨードフェニル基を有する１，３−グリセリド化合物
JP2004064636A (ja) * 2002-07-31 2004-02-26 Fuji Photo Film Co Ltd サブトラクション画像形成方法
JP2004115397A (ja) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd 血管疾患治療薬を含むリポソーム
US7219018B2 (en) * 2003-09-11 2007-05-15 Franco Vitaliano Quantum information processing elements and quantum information processing platforms using such elements
US7216038B2 (en) 2003-09-11 2007-05-08 Franco Vitaliano Quantum information processing elements and quantum information processing platforms using such elements
US7219017B2 (en) 2003-09-11 2007-05-15 Franco Vitaliano Quantum information processing elements and quantum information processing platforms using such elements
US7393924B2 (en) * 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
US20060239925A1 (en) * 2005-04-21 2006-10-26 Konica Minolta Medical & Graphic, Inc. Method of manufacturing pharmaceutical preparation containing liposomes
JP2006335745A (ja) * 2005-06-06 2006-12-14 Fujifilm Holdings Corp リポソームを含むｍｒｉ造影剤
US11096901B2 (en) 2009-03-06 2021-08-24 Metaqor Llc Dynamic bio-nanoparticle platforms
US11235062B2 (en) * 2009-03-06 2022-02-01 Metaqor Llc Dynamic bio-nanoparticle elements
JP6867639B2 (ja) * 2016-10-11 2021-05-12 学校法人 聖マリアンナ医科大学 非イオン性ヨード造影剤の結合体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2157283B (en) * 1984-03-30 1987-07-08 Squibb & Sons Inc Esters of 3,5-diacetylamino-2,4,6-triiodobenzoic acid as x-ray contrast agents
SE9101709L (sv) * 1991-06-03 1992-12-04 Karlshamns Lipidteknik Ab Lipidderivat som diagnostikum eller kontrastmedel
DE19606326A1 (de) * 1995-02-09 1996-08-22 Schering Ag Kontrastmittelhaltige Liposomenformulierung sowie deren Verwendung für die In-vivo-Diagnostik, insbesondere für die Darstellung des Intravasalraumes
CA2187427A1 (en) * 1995-02-24 1996-08-29 Herve Tournier Liposome suspensions as blood pool imaging contrast agents
AU5187696A (en) * 1995-03-09 1996-10-02 Nanosystems L.L.C. Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRAUSE W.: "Delivery of diagnostic agents in computed tomography." ADVANCED DRUG DELIVERY REVIEWS, 37/1-3 (159-173). REFS: 81 ISSN: 0169-409X CODEN: ADDREP, 1999, XP002302389 *
See also references of WO0182977A1 *
SEEVERS R H ET AL: "Potential tumor- or organ-imaging agents. 23. Sterol esters of iopanoic acid." JOURNAL OF MEDICINAL CHEMISTRY. DEC 1982, vol. 25, no. 12, December 1982 (1982-12), pages 1500-1503, XP002301540 ISSN: 0022-2623 *

Also Published As

Publication number Publication date
US20030180220A1 (en) 2003-09-25
EP1284146A4 (de) 2004-12-22
KR20020093957A (ko) 2002-12-16
NZ522457A (en) 2004-07-30
DE60128800D1 (de) 2007-07-19
AU2001252603B2 (en) 2005-10-13
CA2407654C (en) 2009-06-30
WO2001082977A1 (fr) 2001-11-08
DE60128800T2 (de) 2008-02-07
CA2407654A1 (en) 2002-10-28
AU5260301A (en) 2001-11-12
ATE363920T1 (de) 2007-06-15
EP1284146B1 (de) 2007-06-06
US7101532B2 (en) 2006-09-05
KR100824068B1 (ko) 2008-04-21

Similar Documents

Publication Publication Date Title
US20240148913A1 (en) Liposomal nanocarrier delivery system for targeting active cd44 molecule,preparation method therefor, and uses thereof
US7101532B2 (en) Liposome containing hydrophobic iodine compound
KR100889139B1 (ko) 이리노테칸 제제
JP6824452B2 (ja) 感熱性ナノ粒子製剤およびその製造方法
JP2008501667A (ja) 治療および／または診断用途のためのリポソーム集合体
JP2003530362A (ja) 診断剤をターゲッティングするための脂質ベースの系
US8241663B2 (en) Liposome preparation
KR20150078952A (ko) 활성 성분 및 조영제를 포함하는 리포좀 및 그의 용도
US20050008664A1 (en) Compositions and methods related to lipid:emodin formulations
EP1287833B1 (de) Hydrophobe Iodverbindung enthaltendes Liposom und dieses enthaltendes Röntgenkontrastmittel
JPWO2013176223A1 (ja) 炎症性疾患治療用医薬組成物
EP1044679B1 (de) Stabile Liposomen für Gezielte Arzneimittlelgabe
JP5638204B2 (ja) 経口投与用リポソーム製剤およびその製造方法
JP2003055196A (ja) 疎水性ヨード化合物を含むリポソーム及び該リポソームを含むｘ線造影剤
JP2003055267A (ja) 疎水性の放射性ヨード化合物を含むリポソーム
US20070189973A1 (en) Contrast medium comprising liposomes containing hydrophobic chelate compound
JP2003055268A (ja) 疎水性ヨード化合物を含有するリポソームを含むｘ線造影剤
JP2005170807A (ja) 抗体を含むリポソーム
Scherphof et al. In Vivo Uptake and Processing of Liposomes by Parenchymal and Non-Parenchymal Liver Cells; Application to Immunotherapeutic Treatment of Hepatic Metastases
JP2004115378A (ja) 水溶性ヨード化合物を含むリポソーム
US20030064415A1 (en) Method for preparing cell culture system
JP2003128591A (ja) 疎水性ヨード化合物を含むリポソームの製剤方法とこれを用いたリポソーム製剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021114

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041105

17Q First examination report despatched

Effective date: 20050408

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FUJIFILM CORPORATION

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60128800

Country of ref document: DE

Date of ref document: 20070719

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070917

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071106

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070907

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

26N No opposition filed

Effective date: 20080307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070606

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20170426

Year of fee payment: 17

Ref country code: DE

Payment date: 20170420

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180315

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60128800

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430